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V alvular heart disease is a growing clinical problem withsignificant morbidity and mortality. Surgical valve
replacement using mechanical or tissue prosthesis has
remained the preferred therapy for several decades. In
contrast to mechanical valves, the use of bioprosthetic valves
to treat significant aortic valve stenosis (AS) or aortic valve
regurgitation (AR) in the native aortic valve has continued to
increase over time.1,2 Bioprosthetic valves are advantageous
to patients as they negate the need for long-term anticoag-
ulation therapy; however, they have limited durability and are
expected to degenerate within 5 to 20 years.2–4 The current
standard of care for patients with a degenerated bioprosthetic
valve is surgical valve replacement; however, the morbidity
and mortality for reoperation is significant because of the
technical complexity of the re-do sternotomy, and also
because most of these patients are elderly with multiple
comorbid conditions such as prior coronary artery bypass
surgery, diabetes mellitus, and cerebrovascular disease.2,5,6
Although transcatheter heart valves (THV) were initially
designed to treat aortic stenosis, the design yields to its
use for other indications. The first use of a THV device to
treat a failing bioprosthetic heart valve in the aortic position
was reported in 2007.7 Since then, valve-in-valve (VIV) has
become a feasible alternative for treating patients who have
degenerated bioprosthetic aortic valves and who are at
increased risk of adverse perioperative events.2,5,6 VIV is
also emerging as a treatment option for patients with failed
bioprosthesis in the mitral position. Hundreds of
patients with failed mitral bioprosthesis have been treated
worldwide with the off-label use of aortic transcatheter
heart valves.8,9
The procedural success rate for aortic VIV transcatheter
aortic valve replacement (TAVR) was 93.1% based on the
preliminary data from the Valve-in-Valve International Data
(VIVID) registry.6 In the VIVID registry, the overall 1-year
survival was 83.2% in patients who underwent transcatheter
VIV implantation for degenerated bioprosthetic aortic valves.6
The US Food and Drug Administration had approved an
expanded indication for the use of the balloon-expandable
Sapien, Sapien XT valves (Edwards Lifesciences), and the self-
expanding CoreValve System (Medtronic Inc) for aortic VIV
implantation. The Sapien 3 (S3) (Edwards Lifesciences) valve
is the latest iteration of the US Food and Drug Administra-
tion–approved balloon-expandable THV, and it has unique
characteristics compared with previous valves. The use of S3
THV was expanded by the US Food and Drug Administration
on June 5, 2017 not only for VIV implantation inside a failed
bioprosthetic aortic valve, but also for a failed bioprosthetic
mitral valve; this is the first approval of any THV for both
aortic and mitral VIV implantation.
Several new features of the S3 THV, especially its outer
skirt and the ability to overexpand its stent frame,10 may have
an impact for choosing the optimal size of S3 THV for aortic
and mitral VIV implantation.
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In this article we evaluate existing methods with respect to
utilization of the S3 valve in aortic and mitral VIV procedures,
describe bioprosthetic valve sizing terminology (Figure 1), and
discuss preprocedural sizing as well as relevant intraproce-
dural factors and techniques used for a successful VIV
implant.
Sizing and Deployment
In general terms, “under/oversizing” refers to the degree to
which a THV is smaller/larger than the measured annulus or
bioprosthesis internal diameter, respectively. A degree of
oversizing is essential—particularly when implanting self-
expanding valves—to ensure THV anchoring and stability after
deployment. During native valve TAVR, excessive oversizing
may increase the risk of heart block requiring permanent
pacemaker implantation and annulus rupture. How much
oversize is required to ensure adequate fixation and at the
same time avoid incomplete device expansion of balloon-
expandable THVs is unclear, and hence an oversize in the
range of 2 to 3 mm is usually practiced.
In this review, “under/overexpansion” refers specifically to
the balloon filling volume strategy used to deploy the S3 THV,
with reference to the nominal filling volume. For example,
overexpansion of the 23-mm S3 THV, with an extra 2 mL of
filling volume, results in a prosthesis diameter of 24 mm—
mainly at the in- and outflow part of the valve frame—while
preserving normal valve function.10 This under/overexpansion
capability of the S3means that the size of the implanted THV can
be more precisely tailored to the dimensions of the bioprosthe-
sis duringVIVprocedures, thus avoiding excessive oversizing. As
a general principle during VIV procedures, we recommend
implanting the smallest size S3 device that can be adequately
deployed and anchored to achieve a minimum of 1 mm
oversizing (Figure 2), within the constraints of the bioprosthesis
and notwithstanding other anatomical considerations.
Foreshortening
Unlike preceding iterations of balloon-expandable THV, S3
foreshortening during deployment occurs almost exclusively
from the inflow side of the device. This technical feature has
implications when choosing the deployment height of the valve,
particularly as deliberate under- or overexpansion will result in a
lesser or greater degree of foreshortening, respectively.
Appropriate Valve Expansion
Appropriate S3 expansion is important to achieve an optimal
hemodynamic outcome. An inadequately expanded THV may
be at risk of elevated transvalvular gradient because of
inadequate leaflet expansion and mobility, also potentially
increasing the risk of accelerated leaflet degeneration.1,2,4,11
Measure of VIV Success
The requirements for a successful VIV implantation are as
follows: secure anchoring of the THV within the failed
bioprosthesis, a good seal around the valve to eliminate
intervalvular leak, patent coronary arteries (in aortic VIV) and
left ventricular outflow tract (in mitral VIV), a low gradient
across the newly implanted THV, and lack of central
regurgitation. Selection of the appropriate size THV and
preprocedural identification of potential complications are key
to a successful VIV procedure.
Identification and Sizing of the Failed
Bioprosthetic Valve
An important component of performing the VIV procedure
starts with an in-depth understanding of the failed
Figure 1. Surgical bioprosthesis sizing terms. A schematic repre-
sentation of a cross-section through a failed bioprosthetic valve is
shown. Valve size measurements may be defined in a number of
ways. Manufacturer label size is variable and does not usually
indicate the internal diameter of the valve. S-ID is used to indicate the
inner diameter of the valve struts/frame, including overlying fabric.
T-ID accounts for the leaflets and sutures (represented in blue) sewn
within the stent frame,whereasCT-IDalso includes any accumulated
pannus or calcification (represented in orange) within the degener-
ated bioprosthesis. CT-ID indicates computed-tomography inner
diameter; S-ID, stent inner diameter; T-ID, true inner diameter.
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bioprosthetic valve, which includes the following: the type of
valve used (stented, stentless, sutureless, transcatheter
valve), its structural elements, the technical details of the
primary valve surgery (intra-annular versus supra-annular),
and the cause of bioprosthetic valve failure (wear and tear,
calcification, endocarditis, thrombosis, leaflet dysfunction,
and pannus formation).1,2,4,5,12 Selection of the THV size for
the aortic and mitral VIV implantation depends on many
factors listed above.
Failed Bioprosthetic Valve Inner Diameter
The type of bioprosthesis and manufacturer-defined label
size could be obtained from the operative report. When
this information is not available, the type of implant may
be identified by fluoroscopy, chest radiograph, and/or
cardiac multidetector computed tomography (MDCT).5
The sizing and labeling of the surgical bioprosthetic
valves are not standardized and vary widely based on the
different manufacturers. The minimum internal diameter
of the surgical bioprosthetic valve may vary markedly
from the given labeled valve size1,2,4,5 (Figure 1); label
size alone is therefore not suitable as a guide to THV
size selection.
The “true” inner diameter (T-ID) of the surgical biopros-
thesis is one of the most important pieces of information
needed for selecting the size of the THV for the aortic or
mitral VIV procedure.4 It is important to note that most
bioprosthetic valves have a “stent” inner diameter, which
consists of the frame/skeleton of the valve, including the
overlying fabric, and the T-ID, which takes into account the
leaflets sewn within the valve frame13 (Figure 1). The term
“neo-annulus” has been used to describe the narrowest
physical plane—determined in vitro by balloon inflation—of a
surgical bioprosthesis, and it is this benchtop dimension that
determines the T-ID. In most bioprosthesis types, this
minimum diameter is located at the level of the sewing
ring.14 Another crucial point to remember is that when we
factor in the additional space taken up by degenerated
leaflets and accumulated material in the failed bioprosthesis
including pannus formation, the actual internal diameter of
that valve is likely to be even less than the T-ID. In addition to
providing information regarding the degree and distribution of
calcific degeneration, accumulated material at the level of the
sewing ring within a bioprosthesis can be assessed using
contrast-enhanced MDCT. We propose using the definition
“CT” inner diameter (CT-ID) to describe this minimum internal
diameter in degenerated in vivo bioprosthetic valves
Figure 2. Algorithm for determining the choice of S3 THV size. This simplified flow chart can be used
during VIV TAVR to facilitate selection of the S3 THV size, and guide when balloon sizing may be
appropriate. A minimum of 1 mm oversizing is required in order to ensure adequate anchoring of the S3
THV within the bioprosthesis. Use of the smallest possible THV reduces the risk of excessive flaring of the
outflow portion of the stent frame. N.B. In small bioprosthetic valves (label size ≤21), the risk of patient–
prosthesis mismatch is high after VIV TAVR. High-pressure balloon postdilatation with bioprosthetic valve
fracture may enable implantation of a larger size THV with improved transvalvular gradient. CT-ID indicates
computed-tomography inner diameter; S3, Sapien 3; THV, transcatheter heart valve; T-ID, true inner
diameter; VIV TAVR, valve-in-valve transcatheter aortic valve replacement.
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(Figure 1). Use of the CT-ID may indicate that a smaller S3
valve is preferable in order to achieve an optimal VIV result
(Figures 3 and 4).
In order to facilitate suitable valve sizing, Bapat et al have
developed a mobile app “ViV Aortic” and “ViV Mitral” in
collaboration with the technology company UBQO.15 This app
provides data that guide proper identification of all available
surgical and transcatheter valves and rings, as well an in vitro
estimate of the valve T-ID, and sizing recommendation for the
S3 THV.3 Although the ViV App (version 2.0) is invaluable,
there are a few limitations of this App when using the Edwards
S3 valve for VIV. The ViV App sizing recommendation may in
some cases exceed the optimal THV size for a selected
bioprosthesis. For example, the 21-mm Perimount valve
(Edwards Lifesciences) has a 19-mm T-ID, and the App
recommends selecting a 23-mm Sapien XT or S3 THV
(Edwards Lifesciences).3 This may lead to inadequate expan-
sion of the 23-mm valve within the bioprosthesis frame,
leading to prosthesis–patient mismatch with possible higher
transvalvular gradients and inadequate function of the valve
leaflets, and hence a 20-mm Sapien 3 could be a better option
with just 1-mm oversizing. In this situation, our preferred
approach is to use high-pressure postdilatation after 20-mm
S3 valve deployment to optimize expansion and stretching of
the bioprosthetic frame and sewing ring16 or consider
implanting a supra-annular THV; however, if there is adequate
space in the aortic root, then “cracking the ring” with high-
pressure postdilatation technique (described below) can
enable implantation of a 23-mm S3 THV (Figure 5).
Balloon-Sizing and Tug-Test
Balloon sizing is not routinely recommended in VIV proce-
dures, as there is an increased risk of embolization or
creating aortic insufficiency,1,2,4,6 which can result in acute
hemodynamic instability. However, in addition to selecting
the size of the THV based on the T-ID of the initially
implanted bioprosthetic valve, balloon sizing can provide
additional information and better understanding in selected
cases such as when the CT-ID suggests a smaller size S3
may be suitable, borderline valve sizes, stentless biopros-
theses, or valves with a high risk of coronary artery
obstruction. In these situations, balloon sizing can be
performed along with a tug-test (Figures 4 and 6). The tug-
test involves applying negative tension to the fully inflated
balloon within the bioprosthetic valve to help assess how
well the balloon is anchored in the valve. This information
can be used to guide the selection of the appropriate THV
Figure 3. Central regurgitation after extensive oversizing of a 26-mm S3 THV within a St. Jude Epic 27-mm bioprosthesis in the mitral
position. Although the T-ID of the 27-mm St. Jude Epic is 22.5 mm, a mean preoperative CT-ID of 18.2 mm was measured in this degenerated
bioprosthesis (Panel A1). The VIV app recommends use of a 26-mm S3 THV; however, deployment resulted in underexpansion of the device
within the bioprosthesis and extensive flaring of the outflow portion of the frame (Panels B1 to B4), associated with central regurgitation
(Panels C1 and C2). CT-ID indicates computed-tomography inner diameter; S3, Sapien 3; THV, transcatheter heart valve; T-ID, true inner
diameter; VIV, valve-in-valve.
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size and to assess the solidity of any material that may be
accumulated within the bioprosthesis.
Balloon sizing can be useful when the pre-existing valve is
supra-annular with external leaflets, such as the Mitroflow
(Sorin) and Trifecta (Abbott), and there is a short distance to
the coronary ostia, thereby increasing the risk of coronary
artery obstruction.2,4–6 Furthermore, balloon sizing may be
useful to assess for height of the prosthetic valve neo-annulus
and to assess for unanticipated expansion of a stentless
bioprosthesis, a technical issue that can lead to THV
embolization.17
Prosthesis–Patient Mismatch
Prosthesis–patient mismatch (PPM) is the phenomenon when
the implanted prosthetic valve has a lower effective orifice area
(EOA) than a normal human valve.18 Calculations based on
patients’ body surface area, direct measurements of the aortic
root during surgery, and echocardiographic parameters such as
transvalvular gradient and EOA are calculated to assess PPM. In
general, an echocardiographically derived prosthetic EOA,
indexed to body surface area (indexed EOA), of ≤0.60 cm2/m2
is considered severe, of 0.60 to 0.85 cm2/m2 is moderate, and
≥0.85 cm2/m2 is considered nonsignificant.19–21 Based on the
surgical literature, severe PPM following aortic valve replace-
ment is associated with worse clinical outcomes, less reduction
in left ventricular mass, and lower long-term survival.22,23
Likewise, severe PPM following surgical mitral valve replace-
ment is also associated with lower long-term survival.24
Aortic VIV procedures are associated with a higher rate of
PPM than native valve TAVR,6,25 particularly in surgical valves
with a manufacturer size of ≤21 mm.25 Results from the VIVID
registry revealed an elevated postprocedural mean aortic
transvalvular gradient of ≥20 mm Hg in 28% of patients.
When considering a VIV procedure, it is important to
determine whether a high gradient across a surgical valve is
because of degeneration of the valve or simply as a result of
postoperative PPM.26 A VIV procedure will not correct a stable
elevated transvalvular gradient caused by surgical PPM unless
an adjunctive technique—such as bioprosthetic ring fracture
—can be used.
Treatment of small bioprosthetic valves (label size ≤21 mm)
remains a challenging problem during aortic VIV procedures
because of the risk of high postprocedural transvalvular
gradient with new, or persistent, PPM.6 As a result, a
preprocedural evaluation of the EOA may be particularly
Figure 4. Mitral VIV. S3 valve choice based onCT-ID, balloon-sizing, and tug-test. Case of S3 26-mmvalve inside an Epic 31 mm (St. JudeMedical)
with a T-ID of 26.5 mm. The VIV Mitral App recommends implanting a S3 29-mm valve. Based on the CT-ID of 18.7 mm and balloon-sizing and tug-
test with a 25-mm balloon, the decision was to deploy a 26-mm S3 valve with nominal filling volume. A1. Epic 31-mm (St. Jude Medical) valve: CT-ID
wasmeasured at 18.7 mm. A2. Aorto-mitral angle: 138 degrees. B1. Coplanar view of the mitral valve. B2. Balloon-sizing and tug-test with a 25-mm
Edwards balloon. B3. S3 26-mm positioning towards left ventricle because of expected underdeployment. B4. S3 26-mm implantation result with a
flared frame on the ventricular side. B5. Left ventricular angiography to assess for MV regurgitation. B6. S3 26-mm “round” deployment. CT-ID
indicates computed-tomography inner diameter; MV, mitral valve; S3, Sapien 3; T-ID, true inner diameter; VIV, valve-in-valve.
DOI: 10.1161/JAHA.117.007767 Journal of the American Heart Association 5
Use of the Sapien 3 THV for VIV-TAVR and TMVR Shivaraju et al
C
O
N
T
E
M
P
O
R
A
R
Y
R
E
V
IE
W
D
ow
nloaded from
 http://ahajournals.org by on June 11, 2020
important to determine appropriate clinical management and
THV implantation strategy; however, in selected cases the
benefit of acute gradient reduction and hemodynamic improve-
ment in highly symptomatic patients at prohibitive risk of re-do
surgery may, nevertheless, outweigh the risk of PPM that can
occur after a VIV procedure. More recently, deliberate biopros-
thetic sewing ring fracture (discussed below) using high-
pressure balloon dilatation (“cracking-the-ring”) has emerged
as a promising adjunct for aortic VIV in a small bioprosthesis in
order to facilitate implantation of a larger THV size and
effectively reduce postprocedural gradients.27,28
Balloon-Inflatable Versus Self-Expanding
THVs in VIV Procedures
Registry and in vitro data suggest that supra-annular THVs are
associated with lower gradients after aortic VIV procedures;
however, technical factors, such as future access to the
coronary vessels, concerns about THV recoil associated with
self-expanding devices, or use of deliberate bioprosthetic ring
fracture, may prompt selection of a balloon-expandable intra-
annular THV.11,16,29–32 While randomized comparisons of the
transvalvular gradient after S3 versus supra-annular THV
implantation in surgical bioprostheses have not been per-
formed, accurate sizing, positioning, and deployment of the
S3 is clearly essential in order to achieve a good functional
outcome with low transvalvular gradients.
It should be noted that because of anatomical constraints,
balloon-expandable valves are currently mandated in mitral
VIV procedures.
Anticipating Complications During VIV
Procedures
The risk of potential complications can often be determined
by rigorous evaluation of preprocedural investigations. The
Figure 5. Examples of using high-pressure postdilatation to optimize THV deployment in small bioprosthetic valves. Contrast and brightness are
adjusted tominimize blooming artifact. A. Edwards S320-mmTHV inside a Perimount 21 valve (true inner diameter 19 mm). A1. Stent inner diameter
of the Perimount sewing ring measured on the baseline CT—18.1918.9 mm. A2. Twenty-mm S3 angiographic appearance after deployment. Note
the waist appearance at the level of the sewing ring. A3. Angiographic appearance of the 20-mmS3 after postdilatationwith a 20-mm TrueDilatation
balloon (Bard) to 16 atmospheres showing improved device expansion within the bioprosthesis. A4. Stent inner diameter of the Perimount sewing
ring on CT after high-pressure postdilatation showing increased dimensions of 18.9920.1 mm. A residual transvalvularmean gradient of 12 mmHg
was observed on echocardiography. B. Edwards S3 23-mmTHV inside a Perimount 21 valve (true inner diameter 19 mm). B1. Stent inner diameter of
the Perimount sewing ring measured on the baseline CT—18.4920.2 mm. B2. Twenty-three-mm S3 angiographic appearance after deployment.
Note themildwaist appearance at the level of the sewing ring. B3. Angiographic appearance of the 23-mmS3 after postdilatationwith a 22-mmAtlas
Gold balloon (Bard) to 20 atmospheres showing improved device expansion within the bioprosthesis. B4. Stent inner diameter of the Perimount
sewing ring on CT after high-pressure postdilatation showing increased dimensions of 20.2920.1 mm. A residual transvalvular mean gradient of
18 mm Hg was observed on echocardiography. CT indicates computed tomography; S3, Sapien 3; THV, transcatheter heart valve.
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MDCT data, in particular, provide valuable information when
assessing the risk of severe intraprocedural complications.
During aortic VIV procedures, coronary artery occlusion
may occur because of impingement of displaced surgical
leaflets and/or bulky degenerative material on the coronary
ostia, especially in stentless valves and valves with leaflet
attachment outside the frame, such as the Mitroflow (Sorin
Group) and the Trifecta (Abbott) valves. In this regard, MDCT
enables accurate assessment of the height of the coronary
ostia in relation to the surgical bioprosthesis and the width of
the aortic sinus. Low coronary height (<12 mm) and/or small
sinus of Valsalva diameter (<30 mm) will increase the risk for
coronary artery obstruction during native valve TAVR,33 and
aortic VIV procedures are associated with a higher risk.29
Unfavorable anatomy identified on MDCT may prompt avoid-
ance of a VIV procedure altogether; it may also direct the
implanter to use balloon sizing, or use a risk-minimization
strategy, such as less aggressive valve oversizing and deeper
valve implantation, to avoid coronary artery occlusion. A
recently described first-in-humans procedure involving inten-
tional laceration of the bioprosthetic leaflet scallop before
valve implantation (BASILICA) may enable a successful aortic
Figure 6. Balloon-sizing, tug-test, and S3 overdeployment. Case of S3 23-mm valve inside a Mitroflow
27-mm valve with a T-ID of 23 mm. The VIV Aortic App recommends implanting a S3 26-mm valve in this
circumstance. Planned overdeployment of a S3 23-mm (+2 mL in deployment-balloon) THV after balloon-
sizing and tug-test with a 23-mm balloon. A. Coplanar View. B. Balloon sizing and the tug-test show that the
coronary arteries are not obstructed, and the balloon is fixed in the bioprosthetic surgical valve.
C. Placement of the S3 23-mm middle marker is at the bottom of the suture ring of the bioprosthetic
surgical valve (“low position”). D. Implantation result shows no aortic insufficiency with a peak-to-peak
gradient of 5 mm Hg across this valve. S3 indicates Sapien 3; THV, transcatheter heart valve; T-ID, true
inner diameter; VIV, valve-in-valve.
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VIV procedure despite a high risk of coronary occlusion
(unpublished data—TCT 2017).
Mitral VIV poses a unique set of challenges to the operator.
Closing pressure is higher across bioprosthetic valves in the
mitral position when compared with those in the aortic
position; this is because of exposure to left ventricular
systolic, rather than aortic diastolic, pressure. For this reason,
secure anchoring of a VIV THV may be more important in the
mitral position than the aortic. The principles of MDCT-based
valve sizing also apply to mitral VIV.
Mitral VIV also carries with it a risk of left ventricular outflow
tract (LVOT) obstruction because of displacement of the
bioprosthetic leaflets and coverage of the open part of the
THV frame. Mitral VIV-induced LVOT obstruction with hemody-
namic compromise is a serious complication with limited
treatment options and can be fatal; therefore, it should be
avoided whenever possible. Bioprostheses with bovine pericar-
dial leaflets are at particular risk of creating a LVOT obstruction
because the leaflets are positioned higher up the stent frame,
thus resulting in greater THV frame coverage in the LVOT.
Assessing the LVOT tract anatomical morphology with MDCT
can be helpful to identify patients at high risk of this
complication.34 Prominent septal hypertrophy and a narrow
aorto-mitral angle increase the risk of subsequent LVOT
obstruction. The aorto-mitral-annular angle—defined as the
angle formed at the intersection of lines running through the
intercommissural diameter of the mitral annulus and the center
of the aortic annulus—is readily determined from preprocedural
MDCT images. Acute angles<115degreesmay increase the risk
of LVOT obstruction after deployment of a balloon-expandable
valve35 (Figure 4). Preprocedural virtual valve implantation,
performed using commercially available 3-dimensional recon-
struction software, and calculation of the neo-LVOT area can
assist preemptive identification of this complication (Figure 7).
Preliminary studies suggest that a neo-LVOT area of 250 mm2or
larger is associated with a low risk of LVOT obstruction.36,37
Our S3 THV Sizing Recommendation for VIV
Implantation
When using the S3 THV for VIV, we recommend a minimum
oversizing of 1 mm in relation to the T-ID. However, when the
measured CT-ID suggests that a smaller size THV could be
selected, we would recommend balloon sizing and tug testing
to confirm adequate anchoring before implanting the smaller
size. A simple algorithm for choosing the S3 THV size is
provided in Figure 2. In borderline cases between 2 S3 THV
sizes (oversizing range of 0–1 mm based on T-ID or CT-ID),
the smaller S3 valve can be safely overexpanded in order to
optimize valve leaflet function and ensure anchoring10
(Figure 6). Furthermore, overexpansion by overfilling of the
deployment balloon with additional volume results in further
flaring, mainly of the in- and outflow segments of the S3
valve10; this may also play a role in better fixation of the S3
THV within bioprosthetic surgical valves. During mitral VIV
procedures in particular, some degree of flaring of the
ventricular portion of the S3 is recommended to avoid late
atrial dislodgement.34
Surgical Bioprosthetic Sizing Charts
Tables S1 and S2 show the published T-ID, available in the
Aortic VIV and Mitral VIV apps, for selected stented biopros-
thetic valves, in the aortic and mitral positions, respectively.
We recommend ≥1 mm oversizing when implanting a S3 THV
within a stented bioprosthesis. Based on this recommenda-
tion, a smaller S3 could be utilized in a number of cases
compared with the VIV app recommendation. For example,
the 27-mm Mitroflow valve (Sorin) has a T-ID of 23 mm and
the ViV Aortic App recommends selecting a 26-mm S3 valve.3
However, an overdeployed 23-mm S3 valve achieved an
excellent final result (Figure 6).
Stentless and Sutureless Surgical
Bioprosthetic Valves
The surgical technique used for implantation of stentless and
sutureless bioprosthetic valves could vary the T-ID of these
valves. Walther et al described implantation of oversized
stentless surgical valves in patients with a small aortic root
using controlled oversizing and adjusting the valve size to the
sinotubular junction diameter.38 They were able to achieve a
gain of 2 to 4 mm in prosthesis size with improved
hemodynamics based on this controlled oversizing.38 Thus,
for stentless and sutureless surgical valves (Table S3) we
recommend MDCT-based sizing. Measurement of the CT-ID,
which matches with the internal diameter of the sewing ring
(“neo-annulus”), and assessment of the amount of degener-
ative material, such as pannus or calcification in and around
the valve, is important and should be taken into consideration.
Valve in THV
Because of the recent popularity of TAVR, failed THVs are
likely to account for an increasing proportion of VIV proce-
dures. Because of the common practice of oversizing self-
expanding transcatheter valves, and the variability in final
internal diameter, CT measurements of the size of the native
annulus should be taken into consideration. In the majority of
patients with a prior Sapien, Sapien XT, or S3 valve, the same
size S3 THV can be implanted. For example, if a patient has a
failed 23-mm Sapien XT valve, then we would recommend
implanting a 23-mm S3 THV inside this failed THV.
DOI: 10.1161/JAHA.117.007767 Journal of the American Heart Association 8
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Intraprocedural Considerations: Aortic VIV
To facilitate accurate THV landing zone evaluation, stented
surgical valves should be aligned fluoroscopically so that the
basal ring and struts form a single plane perpendicular to the
imaging beam. This coplanar view can usually be achieved by
aligning the stent strut tips, the suture ring of stented valves,
or the nadir points of stentless valves39 (Figure 8).
To ensure an optimal valve deployment with safe anchoring
and good sealing, the skirt of the S3 valve should be
implanted at the height of the “neo-annulus” of the surgical
bioprosthetic valve. The neo-annulus is almost always located
at the level of the surgical valve sewing ring; however,
fluoroscopic identification of the location of the sewing ring
can vary depending on the valve type.14
In stented valves, the base of the S3 central radiopaque
marker should be placed 3 to 5 mm above the suture ring
when using nominal deployment volumes. In case of the
Mosaic valve (Medtronic), where the top markers of the
outflow struts are the only fluoroscopically visible markers,
the aortic edge of the crimped S3 stent frame should be
placed 2 mm above the aortic edge of the markers in
nominally deployed valves.
In stentless and sutureless aortic bioprosthesis, the “neo-
annulus” should be angiographically aligned and the base of
the S3 central marker should be placed at the height of the
“neo-annulus.” If possible, the frame of the S3 should cover
the neo-annulus and the leaflet of the bioprosthesis. A pigtail
can be positioned in the aortic root to assist accurate
alignment with the annulus.
When treating failed supra-annular and intra-annular TAVR
devices, the S3 should, if possible, be deployed so that its
frame covers the native aortic valve annulus and the leaflets
of the first device.
During deployment of the S3 THV, it should be kept in mind
that the foreshortening of the valve occurs predominantly
A B
C D
Figure 7. Mitral annular area and neo-LVOT area measurements. A, Cardiac computed tomography–
based measurement of the mitral internal annular area using 3Mensio Structural Heart Mitral Workflow
version 8.1 (Pie Medical Imaging, Maastricht, the Netherlands). B, Short-axis view of the mitral
bioprosthesis with a 23-mm virtual valve in place (pink circle). C, Measurement of the LVOT tract area in
systole in short-axis (white circle) view using 3Mensio Structural Heart Mitral Workflow version 8.1 (Pie
Medical Imaging, Maastricht, the Netherlands). D, Measurement of the remaining LVOT area in short axis
(white circle) after placement of the virtual transcatheter heart valve (pink). The remaining space in the
LVOT after placement of the virtual valve is the neo-LVOT. A neo-LVOT area of 250 mm2 or larger is
associated with a low risk of LVOT obstruction. LVOT indicates left ventricular outflow tract.
DOI: 10.1161/JAHA.117.007767 Journal of the American Heart Association 9
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from the inflow side of the valve during the late stage of valve
expansion. For this reason, the deployment height of the S3
during VIV procedures should be adjusted to compensate for
this foreshortening. Figure 8 shows an example of various
coplanar views of surgical bioprosthetic valves, and where to
position the 3-mm-long central marker of the S3 valve in
relation to the suture ring of the aligned surgical valve based
on the predetermined nominal deployment, overexpansion, or
underexpansion THV strategy.
Intraprocedural Considerations: Mitral VIV
The fluoroscopic alignment of the initially implanted mitral
bioprosthesis is performed in a similar manner to Ao VIV
procedures. Based on analysis using the Sapien XT valve, a
THV deployment position that is too far into the ventricle may
be associated with an increased risk of LVOT obstruction.35
For a given valve size, the frame height of the S3 THV is at
least 3 mm greater than the Sapien XT.35 In contrast to the
Sapien XT, foreshortening of the S3 occurs from the atrial side
and the extent is dependent on whether the valve is under-,
over-, or nominally deployed. For this reason, we recommend
that during nominal valve deployment the initial alignment of
the S3 be performed by positioning the ventricular edge of the
frame with the ventricular edge of the bioprosthesis. If an
underexpansion strategy is chosen, then a more ventricular
initial alignment may be necessary to avoid an excessively
atrial implantation; conversely, more atrial alignment may be
useful during planned valve overexpansion in order to avoid an
overly ventricular final position. If the anticipated risk of LVOT
obstruction is not excessive, flaring of the ventricular portion
of the S3 frame with the deployment balloon (nominal filling
volume +1–2 mL) during valve implantation, or postdilatation,
may be considered to reduce the risk of atrial embolization.
Intraprocedural Considerations: Bioprosthetic
Valve Fracture and High-Pressure Balloon
Postdilatation
Small bioprosthetic valves (label size ≤21) treated with VIV
TAVR are at high risk of elevated postprocedural gradient and
patient–prosthesis mismatch. Controlled cracking of the
polyester loop within the valve sewing ring using high-
pressure balloons has been described in vitro and in a small
number of in vivo cases for surgical valves implanted in the
pulmonary position40 with meaningful reductions in postpro-
cedural gradient. In vitro, the frames of the Mitroflow, Magna,
Magna Ease, and Mosaic,27 plus the Biocor Epic and
Perimount40 bioprosthetic surgical valves have been success-
fully fractured using high-pressure True Dilatation and Atlas
Gold balloons (Bard Peripheral Vascular). Balloon-rated burst
pressure was exceeded in all cases and fracture of valves with
metal sewing rings was not possible. Chhatriwalla et al
subsequently reported successful in vivo bioprosthetic valve
fracture—in patients with bioprosthetic valves ≤label size 21
in the aortic position—with a reduction in mean transvalvular
gradient and an increase in valve EOA in 20 consecutive
clinical cases; valve fracture was performed either before or
Figure 8. Coplanar alignment of stented surgical bioprosthetic valves. Varying alignment of the coplanar view: A. Overlap of struts, B. Struts
in 1 line, C. Stent top markers in 1 line. Stented surgical valves can be aligned based on the top markers/struts of the valve, the suture ring, or
angiographically at the nadir of the cusps of the leaflets. The dotted red line represents the suture ring or the stent strut tips of the surgical
valve. The length of the middle marker is 3 mm on the S3 THV. The figure depicts the accurate placement of the S3 THV along the dotted red
line: 1, Predetermined overexpansion (“low position”); 2, Predetermined nominal deployment (3–5 mm above the suture ring); 3, Predetermined
underexpansion (“high position”). S3 indicates Sapien 3; THV, transcatheter heart valve.
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after the VIV TAVR.28 More recently, high-pressure postdi-
latation has been shown to improve transvalvular gradients in
small bioprostheses even if sewing ring fracture is not
achieved.16
Bioprosthetic valve fracture may allow satisfactory deploy-
ment of a larger THV than would otherwise be feasible, thus
potentially correcting pre-existing PPM when treating small
bioprosthetic valves (Figure 5). Care should be taken to
ensure that there is adequate space within the aortic root
anatomy to allow safe implantation of a larger THV.
High-pressure balloon dilatation can be performed before
or after valve implantation. The former strategy may enable
more reliable fracture of the bioprosthetic ring with the
potential disadvantages of inducing hemodynamically unsta-
ble severe aortic regurgitation, and an increased risk of
annulus rupture. The latter approach reduces the risk of acute
valvular insufficiency but may increase the difficulty in
achieving ring fracture and the risk of injuring the THV
leaflets. In most cases our preference is to perform high-
pressure balloon dilatation after implantation of the THV;
however, this novel technique may also be associated with an
elevated risk of embolization of degenerated valve material,
rupture of the aortic root, coronary obstruction, and heart
block.27,28
Conclusion
VIV implantation is a feasible alternative to reoperation for a
failed initial bioprosthetic valve. The use of the S3 THV for VIV
implantation in a failed aortic and mitral bioprosthesis has
recently received US Food and Drug Administration approval;
the outer skirt of the S3 valve and the ability to overexpand its
frame make it a suitable device for the VIV procedure. The
selection of the S3 size should be based on the T-ID of the
initially implanted bioprosthetic valve; however, CT imaging
and determination of the CT-ID may influence the choice of S3
THV size in VIV procedures.
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 Table S1. STENTED BIOPROSTHETIC SURGICAL AORTIC VALVES 
Manufacturer valve size and internal diameter of selected commercially available stented surgical 
aortic valves are displayed. The published “true” internal diameter (T-ID) for each valve is shown. 
A minimum of 1 mm oversizing based on T-ID is recommended when selecting a S3 THV. 
Coronary height, aortic root width, and valve degeneration based on CT-sizing – with or without 
balloon sizing and tug-test – should also be taken into consideration.  ID = internal diameter 
 
STENTED SURGICAL AORTIC VALVES 
Valve Name Valve Size Height 
Stent ID     
(S-ID) 
True ID       
(T-ID) 
Aspire  
(Vascutek) 
20 16 18.2 16.5 
21 16 19 17.5 
23 17 21 19 
25 18 23 21 
27 18 25 22 
     
Biocor / Epic  
(St. Jude Medical) 
21 14 19 16.5 
23 15 21 18.5 
25 16 23 20.5 
27 17 25 22.5 
29 19 27 24.5 
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 Biocor / Epic Supra 
(St. Jude Medical) 
19 14 19 16.5 
21 15 21 18.5 
23 16 23 20.5 
25 17 25 22.5 
27 19 27 24.5 
     
CE SAV  
(Edwards Lifesciences) 
19 14 18 17 
21 15 20 19.5 
23 16 22 21 
25 17 24 22.5 
27 17 26 24 
29 18 28 25 
31 19 30 27 
     
CE Standard  
(Edwards Lifesciences) 
19 19 17 17 
21 19 19 19 
23 20 21 20 
25 21 23 21 
27 22 25 23 
29 22 27 25 
30 24 29 27 
     
Dokimos  19 14 16 16 
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 (Labcor) 21 15.5 18 18 
23 16.5 20 20 
25 17 22 22 
27 19 24 24 
     
Hancock II  
(Medtronic Inc) 
21 15 18.5 16.5 
23 16 20.5 18.5 
25 17.5 22.5 20.5 
27 18.5 24 22 
29 20 26 24 
     
Intact  
(Medtronic Inc) 
19 13.5 17.5 15.5 
21 15 18.5 16.5 
23 16 20.5 18.5 
25 17.5 22.5 20.5 
27 18.5 24 22 
29 20 26 24 
     
 
Labcor Porcine  
(Labcor) 
19 11 19 17 
21 11 21 19 
23 13 23 21 
25 14 25 23 
27 16 27 25 
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 29 16 29 27 
     
Magna  
(Edwards Lifesciences) 
19 14 18 17 
21 15 20 19 
23 16 22 21 
25 17 24 23 
27 18 26 25 
29 19 28 27 
     
Magna Ease  
(Edwards Lifesciences) 
19 13 18 17 
21 14 20 19 
23 15 22 21 
25 16 24 23 
27 17 26 25 
29 18 28 27 
     
 
Mitroflow  
(Sorin) 
19 11 15.4 15.5 
21 13 17.3 17 
23 14 19 19 
25 15 21 21 
27 16 22.9 23 
29 16 24.7 24.5 
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 Mosaic  
(Medtronic Inc) 
19 13.5 17.5 15.5 
21 15 18.5 16.5 
23 16 20.5 18.5 
25 17.5 22.5 20.5 
27 18.5 24 22 
29 20 26 24 
     
Perimount  
(Edwards Lifesciences) 
19 14 18 17 
21 15 20 19 
23 16 22 21 
25 17 24 23 
27 18 26 25 
29 19 28 27 
     
 
Perimount 2700  
(Edwards Lifesciences) 
19 14 18 17 
21 15 20 19 
23 16 22 21 
25 17 24 23 
27 18 26 25 
29 19 28 27 
     
Soprano  
(Sorin) 
18 12 17.8 18 
20 14 19.8 20 
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 22 15 21.7 22 
24 16 23.7 23.5 
26 18 25.6 25.5 
28 19 27.6 27.5 
     
Trifecta  
(St. Jude Medical) 
19 15 17 16 
21 16 19 18 
23 17 21 20.5 
25 18 23 22 
27 19 25 24 
29 20 27 26 
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 Table S2. STENTED BIOPROSTHETIC MITRAL VALVES 
Manufacturer valve size and internal diameter of selected commercially available stented mitral 
valves are displayed. The published “true” internal diameter (T-ID) for each valve is shown. A 
minimum of 1 mm oversizing based on T-ID is required when selecting a S3 THV. Aorto-mitral 
angulation and valve degeneration based on CT-sizing – with or without balloon sizing and tug-
test – should also be taken into consideration. If the anticipated risk of LVOT obstruction is not 
excessive, flaring of the ventricular portion of the S3 frame with the deployment balloon (Nominal 
filling volume + 1-2ml of additional volume) during valve implantation, or post-dilatation, may be 
considered to reduce the risk of atrial embolization. ID = internal diameter 
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 STENTED SURGICAL MITRAL VALVES 
Valve Name Valve Size Height 
Stent ID     
(S-ID) 
True ID       
(T-ID) 
Biocor / Epic  
(St. Jude Medical) 
25 16 23 20.5 
27 17 25 22.5 
29 19 27 24.5 
31 20 29 26.5 
33 20 31 28.5 
     
CE SAV  
(Edwards Lifesciences) 
25 17 24 22.5 
27 17 26 24 
29 18 28 25 
31 20 30 27 
33 21 32 28 
     
CE Standard  
(Edwards Lifesciences) 
25 19 23 21 
27 21 25 23 
29 23 27 25 
31 24 29 27 
33 25 31 28 
35 26 33 30.5 
     
Hancock II  
(Medtronic Inc) 
25 18 22.5 20.5 
27 19 24 22 
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 29 20.5 26 24 
31 22 28 26 
33 23 30 28 
     
Magna  
(Edwards Lifesciences) 
25 16 25 24 
27 17 27 26 
29 18 29 28 
31 19 31 28.5 
33 19 31 28.5 
     
 
Mosaic  
(Medtronic Inc) 
25 18 22.5 20.5 
27 19 24 22 
29 20.5 26 24 
31 22 28 26 
33 23 30 28 
     
Pericarbon More  
(Sorin) 
19 12 15 15 
21 13 17 17 
23 14 19 19 
25 15 21 21 
27 17 23 23 
29 18 25 25 
31 19 27 27 
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33 20 29 29 
     
Perimount  
(Edwards Lifesciences) 
25 17 25 23 
27 18 27 25 
29 19 29 27 
31 20 31 28.5 
33 20 31 28.5 
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 Table S3. STENTLESS, SUTURELESS AND TRANSCATHETER BIOPROSTETIC 
AORTIC VALVES  
In stentless, sutureless and transcatheter bioprosthetic aortic valves, sizing based on “CT” internal 
diameter (CT-ID) is recommended. A minimum of 1 mm oversizing based on CT-ID, or in the 
case of selfexpanding THVs based on CT measurement of the native aortic annulus, is 
recommended when selecting a S3 THV. Coronary height, aortic root width, and valve 
degeneration – with or without balloon sizing and tug-test – should also be taken into 
consideration. 
STENTLESS, SUTURELESS, TRANSCATHETER BIOPROSTHETIC 
AORTIC VALVES 
Stentless Sutureless Transcatheter 
3F Valve 
(Medtronic Inc) 
Enable 
(Medtronic Inc) 
Accurate TA / Neo 
(Symetis) 
Biovalsalva Porcine Condoit 
(Vascutec) 
Intuity 
(Edwards Lifesciences) 
CoreValve / Evolut 
(Medtronic Inc) 
Cryolive O’Brien 
(Cryolife) 
Perceval 
(Sorin) 
JenaValve 
(JenaValve Technology) 
Freedom Solo 
(Sorin) 
 Lotus / Lotus Edge 
(Boston Scientific) 
Freestyle Root 
(Medtronic Inc) 
Portico 
(St. Jude Medical) 
Freestyle Valve 
(Medtronic Inc) 
Sapien / Sapien XT / Sapien3 
(Edwards Lifesciences) 
Pericarbon Freedom 
(Sorin) 
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Prima Root 
(Edwards Lifesciences) 
Toronto SPV Root 
(St. Jude Medical) 
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